Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From MyoKardia, Inc.
US FDA closed out the month of April with two new molecular entity approvals that address underserved markets but carry some safety concerns.
Bristol already is training cardiologists at major treatment centers in how to treat obstructive hypertrophic cardiomyopathy with Camzyos (mavacamten) based on the REMS in the US label.
Having looked at four prominent drug candidates which are expecting important top-line data this quarter, with the help of Biomedtracker's Q2 Outlook Report, we take a look at four other assets that could soon break into the US market, from infectious diseases to diabetes.
Long-term results from the EXPLORER-HCM extension study are consistent with the pivotal trial in obstructive hypertrophic cardiomyopathy, while data from VALOR may support a supplemental filing.
- In Vitro Diagnostics
Drug Discovery Tools